Is RITEZONE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RITEZONE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RITEZONE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RITEZONE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RITEZONE?
Key metric: As RITEZONE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for RITEZONE. This is calculated by dividing RITEZONE's market cap by their current
earnings.
What is RITEZONE's PE Ratio?
PE Ratio
13.8x
Earnings
₹13.51m
Market Cap
₹186.13m
RITEZONE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
0.6x
Enterprise Value/EBITDA
10.1x
PEG Ratio
n/a
Price to Earnings Ratio vs Peers
How does RITEZONE's PE Ratio compare to its peers?
Price-To-Earnings vs Industry: RITEZONE is good value based on its Price-To-Earnings Ratio (13.8x) compared to the Indian Chemicals industry average (31.2x).
Price to Earnings Ratio vs Fair Ratio
What is RITEZONE's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
RITEZONE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
13.8x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RITEZONE's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.